Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18 FDG and 18 FLT PET

Francis, Daren; Visvikis, Dimitris; Costa, Durval C.; Croasdale, I.; Arulampalam, Tan; Luthra, SK; Taylor, Ian W.; Ell, PJ

doi:10.1007/s00259-003-1438-0

Cited by 15 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concurrently, 18 F-FDG and 18 F-FLT responses were compared after the administration of temsirolimus (a cell cycle-targeting agent). A significantly lower baseline 18 F-FLT uptake than 18 F-FDG uptake was found, which has already been reported for several other tumor types (8)(9)(10)(11)(12) and which made it difficult to adequately delineate tumor volume in 18 F-FLT images. Therefore, this analysis concentrated on the maximal SUVs, the most frequently used parameter for response assessment because of the relative resistance of maximal SUVs to partial-volume effects and interobserver variability.…”

Section: Discussionmentioning

confidence: 60%

¹⁸F-FDG and ¹⁸F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model

Brepoels¹,

Stroobants²,

Verhoef³

et al. 2009

J Nucl Med

View full text Add to dashboard Cite

To be a reliable predictor of response, tracer uptake should reflect changes in the amount of active tumor cells. However, uptake of 18 F-FDG, the most commonly used PET tracer, is disturbed by the inflammatory cells that appear early after cytotoxic therapy. The first aim of this study was to investigate whether 39-18 F-fluoro-39-deoxy-L-thymidine ( 18 F-FLT), a marker of cellular proliferation, is a better tracer for response assessment early after cytotoxic therapy. A second objective of this study was to investigate whether 18 F-FDG and 18 F-FLT responses were comparable early after mammalian target of rapamycin (mTOR) inhibition, as an example of proliferation-targeting therapies. Methods: Severe combined immunodeficient mice were subcutaneously inoculated with Granta-519 cells, a human cell line derived from a leukemic mantle cell lymphoma. Half the mice were treated with cyclophosphamide and the other half with mTOR inhibition. 18 F-FDG and 18 F-FLT uptake was evaluated by small-animal PET on day 0 (D0; before treatment), D11, D12, D14, D17, D19, D111, and D114. At each time point, 2 mice of each treatment condition were sacrificed, and tumors were excised for histopathology. Results: After cyclophosphamide, 18 F-FDG and 18 F-FLT uptake decreased, with a maximum reduction of 229% for 18 F-FDG and 225% for 18 F-FLT uptake at D12, compared with baseline. Although 18 F-FDG uptake increased from D14 on, with a maximum on D17, 18 F-FLT uptake remained virtually stable. Histology showed an increase in apoptotic or necrotic tumor fraction, followed by an influx of inflammatory cells. In mTOR-inhibited mice, 18 F-FDG uptake dropped until D12 after therapy (243%) but increased at D14 (227%) to form a plateau on D17 and D19 (214% and 216%, respectively). Concurrently, 18 F-FLT uptake decreased to 231% on D12, followed by an increase with a peak value of 112% on D17, after which 18 F-FLT uptake decreased again. Cyclin D1 expression dropped from D11 until D14 and returned to baseline at D17. Conclusion: Because 18 F-FLT uptake is not significantly influenced by the temporary rise in inflammatory cells early after cyclophosphamide, it more accurately reflects tumor response. However, a formerly unknown temporary rise in 18 F-FLT uptake a few days after the administration of mTOR inhibition was defined, which makes it clear that drug-specific responses have to be considered when using PET for early treatment monitoring.

show abstract

Section: Discussionmentioning

confidence: 60%

¹⁸F-FDG and ¹⁸F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model

Brepoels¹,

Stroobants²,

Verhoef³

et al. 2009

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…Given the limitations of conventional cross-sectional imaging, the use of functional imaging (with, for example, FDG-PET or FLT-PET) may provide more reliable surrogates of activity to hasten drug development for the treatment of biliary tract cancers (as is currently being investigated for other tumour types, e.g. colorectal cancer (Francis et al, 2004)). …”

Section: Discussionmentioning

confidence: 99%

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study

et al. 2009

View full text Add to dashboard Cite

We assessed the activity of gemcitabine (G) and cisplatin/gemcitabine (C/G) in patients with locally advanced (LA) or metastatic (M) (advanced) biliary cancers (ABC) for whom there is no standard chemotherapy. METHODS: Patients, aged X18 years, with pathologically confirmed ABC, Karnofsky performance (KP) X60, and adequate haematological, hepatic and renal function were randomised to G 1000 mg m À2 on D1, 8, 15 q28d (Arm A) or C 25 mg m À2 followed by G 1000 mg m À2 D1, 8 q21d (Arm B) for up to 6 months or disease progression. RESULTS: In total, 86 patients (A/B, n ¼ 44/42) were randomised between February 2002 and May 2004. Median age (64/62.5 years), KP, primary tumour site, earlier surgery, indwelling biliary stent and disease stage (LA: 25/38%) are comparable between treatment arms. Grade 3 -4 toxicity included (A/B, % patients) anaemia (4.5/2.4), leukopenia (6.8/4.8), neutropenia (13.6/14.3), thrombocytopenia (9.1/11.9), lethargy (9.1/28.6), nausea/vomiting (0/7.1) and anorexia (2.3/4.8). Responses (WHO criteria, % of evaluable patients: A n ¼ 31 vs B n ¼ 36): no CRs; PR 22.6 vs 27.8%; SD 35.5 vs 47.1% for a tumour control rate (CR þ PR þ SD) of 58.0 vs 75.0%. The median TTP and 6-month progression-free survival (PFS) (the primary end point) were greater in the C/G arm (4.0 vs 8.0 months and 45.5 vs 57.1% in arms A and B, respectively). CONCLUSION: Both regimens seem active in ABC. C/G is associated with an improved tumour control rate, TTP and 6-month PFS. The study has been extended (ABC-02 study) and powered to determine the effect on overall survival and the quality of life.

show abstract

“…Poziom 18F-FLT jest proporcjonalny do aktywności kinazy tymidynowej i do innych wskaźników proliferacji, jak np. Ki-67 [18]. FLT nie gromadzi się w stanach zapalnych i umożliwia obrazowanie bardziej agresywnych obszarów w guzie nowotworowym [19].…”

Section: Wstępunclassified

Rola badania PET w leczeniu raka szyjki macicy w doniesieniach na 3rd ESTRO Forum 2015

Burchardt

2017

los

View full text Add to dashboard Cite

StreszczenieW 2015 roku w Barcelonie odbyła się kolejna konferencja naukowa Europejskiego Towarzystwa Radioterapii Onkologicznej (ESTRO). Szczególną uwagę należy poświęcić doniesieniom naukowym dotyczącym roli badań obrazowych z dziedziny medycyny nuklearnej. Jest to temat o coraz większym znaczeniu, który w obecnej chwili jest w centrum zainteresowania wielu specjalistów zajmujących się leczeniem onkologicznym. Także w ginekologii onkologicznej wielu autorów prac przedstawiło swoje badania z zakresu roli badania PET w leczeniu raka szyjki macicy. Abstract:In 2015, the conference of the European Society of Radiation Oncology (ESTRO) was held in Barcelona. Particular attention should be paid to reports in the field of imaging in nuclear medicine. This is an issue of growing importance that attracts attention of many specialists in cancer treatment. There were also many papers related to the role of PET-CT in cervical cancer treatment.

show abstract

Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18 FDG and 18 FLT PET

Cited by 15 publications

References 2 publications

¹⁸F-FDG and ¹⁸F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model

¹⁸F-FDG and ¹⁸F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study

Rola badania PET w leczeniu raka szyjki macicy w doniesieniach na 3rd ESTRO Forum 2015

Contact Info

Product

Resources

About

Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18 FDG and 18 FLT PET

Cited by 15 publications

References 2 publications

18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model

18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study

Rola badania PET w leczeniu raka szyjki macicy w doniesieniach na 3rd ESTRO Forum 2015

Contact Info

Product

Resources

About

¹⁸F-FDG and ¹⁸F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model

¹⁸F-FDG and ¹⁸F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model